LAUSR

Cardiovascular disease (CVD) is common in peritoneal dialysis (PD) patients. This study was designed to investigate the effects of isoflavones on systemic and vascular inflammation markers and oxidative stress in PD patients. In this randomized clinical trial, 40 PD patients were randomly assigned to either the isoflavone or the placebo group. The isoflavone group received 100 mg soy isoflavones daily for 8 weeks, whereas the placebo group received corresponding placebos. At baseline and the end of eighth week, serum high sensitive C‐reactive protein (hs‐CRP), intercellular adhesion molecule type 1 (ICAM‐1), vascular cell adhesion molecule type 1 (VCAM‐1), E‐selectin, and malondialdehyde were measured. Serum VCAM‐1 decreased significantly in the isoflavone group at the end of Week 8 compared to baseline (p = .01), whereas no significant change was observed in the placebo group. Serum ICAM‐1 decreased significantly in the isoflavone (p = .01) and placebo (p = .01) group compared to baseline. However, the reduction of ICAM‐1 was significantly higher in the isoflavone group than in the placebo group (p = .02). There were no significant differences between the two groups in mean changes of serum E‐selectin, malondialdehyde, and hs‐CRP. This study indicates that isoflavones reduce serum VCAM‐1 and ICAM‐1, which are two CVD risk factors, in PD patients.